IOVA
Iovance Biotherapeutics Inc
Mentions (24Hr)
0.00% Today
Reddit Posts
Biotech Short Watchlist Today: IOVA, BDTX, ESPR, SANA, FATE, ALT
Never thought I'd make post like this. $IOVA
Could be a good option if you look into the facts
Is IOVA a fit candidate for a short squeeze?
Short week passed, I still in those shares
The best stock picks for 2026
Your next week moves? Any ideas?
Just an update. IOVA. Bought this morning.
$IOVA Announces Lung Data Pre Market
$IOVA -TIL Therapy Showing Real Teeth in NSCLC (Potential Multi-Bagger Long-Term) - Report dropped 50mins ago
$IOVA - TIL Therapy Showing Real Teeth in NSCLC (Potential Multi-Bagger Long-Term) - Report dropped 50 minutes ago, already subtancially up
[#2 YOLO DD] $IOVA just proved its cancer drug DESTROYS the current standard — this might be the real one 🚀
IOVA at $2.19; 443% Upside Potential in FDA-Approved Cancer Therapy?
OPEN -> DOW + IOVA -> LAC + GPHOF: 570% in 3 months, $12000 -> $68000.
IOVA Due Diligence, why I am investing in it
UPCOMING CATALYSTS! Iovance Biotherapeutics ($IOVA): Saving Lives on a Beautiful, Hard-Fought Path
General question for everyone who are doing some search about IOVA stock, its a cancer therapy . Cancer immunotherapy products
There has been no post on IOVA for last 2 months
Iovance (IOVA) having a nice day—is it a buy for you?
IOVA s got earnings tomorrow, Just praying it doesn t rug me .a green candle would be nice
Man this dumbass recommended a shit stock $IOVA
Got sick of get pounded in IOVA and threw it into SPY puts for Liberation Day round 2
UBS expectations for IOVA earnings call next week
IOVA UBS expectations for next week earnings call
IOVA Is Waking Up — Price Action Screams Breakout, But Fundamentals Demand Patience
Robinhood just liquidated my calendar spread with a week left
How much more can you take from me IOVA
Every time it drops, I'll buy more $IOVA
$IOVA - Am I Too Late to This Rocket Ship, or Is This Just Another Meme Dream? 🚀🤔
IOVANCE (IOVA) is straight-up screaming moooon and heres why
Looks like IOVA and RR might have their
Should I buy $DNUT ($4.13) and $IOVA ($3.13) before market opens?
408K -> 800K YOLO INTO IOVA AND WHY THIS IS JUST THE START
Keep and I on IOVA. It's on the move
Everyone isbuying $OPEN to flip houses while $GERN is flipping death and nobody cares
ASCO coming in hot, I built a mini biotech watchlist before the data flood
DD: PDS Biotechnology (PDSB) — Undervalued Immunotherapy Pioneer on the Verge of a Major Pivot
I am a ex-prop trader and these are the stocks on my watchlist (12/27)
Maybe a possible IOVA Short Squeeze?
Squeeze started in IOVA half days volume in 10 minutes.
5 OTC STOCKS FOR POTENTIAL GROWTH 2024..THOUGHTS?
Biotechs on the Radar Screen: $IOVA, $IBRX, $SILO, $LUMO, $SMMT
Biotechs on the Radar Screen: $IOVA, $IBRX, $SILO, $LUMO, $SMMT
Biotechs on the Radar Screen: $IOVA, $IBRX, $SILO, $LUMO, $SMMT
thought on IOVA looks like it wants to run to 8 bucks at an all time low 1 billion dollar marketcap
IOVA stock gains as Piper sees approval for melanoma therapy this year (NASDAQ:IOVA)
💰💰💰Good morning! #premarket #watchlist 12/5 $IOVA -JMP Securities Hematology and Oncology Summit Fireside Chat: December 7, 2022 at 11:00 a.m., $DUO $ZH -china buzz+no news, $XPEV -earnings
JCSE huge profit opportunity! Now! 3mill Free Float only!
💰Good morning! #premarket #watchlist 05/27 $DIDI -Report Chinese Auto Giant Is Considering Buying Stake , $AVDL -old news , $SEAC -executive officers compensation report, $GPS -Q1 2022 Earnings, $IOVA -data about its melanoma therapy, $PMVP - Phase1 data . Check it all in Realtime Stock Screener!
💰Good morning! #premarket #watchlist 05/27 $DIDI -Report Chinese Auto Giant Is Considering Buying Stake , $AVDL -old news , $SEAC -executive officers compensation report, $GPS -Q1 2022 Earnings, $IOVA -data about its melanoma therapy, $PMVP - Phase1 data . Check it all in Realtime Stock Screener!
💰Good morning! #premarket #watchlist 05/27 $DIDI -Report Chinese Auto Giant Is Considering Buying Stake , $AVDL -old news , $SEAC -executive officers compensation report, $GPS -Q1 2022 Earnings, $IOVA -data about its melanoma therapy, $PMVP - Phase1 data.
$IOVA and $CCL are two tickets setting up for a bullish play. CCL over $21.65 and IOVA over $20 could be decent short term swing trades. Just based on technical analysis and Support/Resistance lines.
$IOVA and $CCL are two tickets setting up for a bullish play. CCL over $21.65 and IOVA over $20 could be decent short term swing trades. Just based on technical analysis and Support/Resistance lines.
$IOVA is a potential biotech company to invest in.
Mentions
just listening to IOVA conference call. bought 100 shares earlier so i guess i have to pay attention. Australia FDA approval for melanoma therapy. this could be s/thing! Mrkt cap: $2b so price movement will be slow
POV: YOU BOUGHT IOVA BECAUSE IT’s the ONLY BIOTECH STARTUP FOR CANCER
Its up 50% YTD, this dude just bought at a shit time. I own IOVA at like 2.40 average, up about 70%
$IOVA is your second chance.
IOVA moving up this morning on no news
I'm in IOVA. Hope for great future for both
Healthcare down right now but im in a bunch of IOVA, pharma play with 10 bagger potential
Am I the only one holding IOVA? 22500 @ $3.65. Lets gooooo
I’ve got 22,500 shares of IOVA @ 3.65. Earnings tomorrow morning. 31% of float is short. I’m ready.
IOVA earnings are tomorrow morning. I’ve got 22500 shares and I’m ready to see $10+ when this squeezes. Let’s goooo
Bought $1500 of NOW, $500 of IOVA, $200 of HOVR. All new positions. Looking at MRLN, any reason it’s down today ?
The things being done to IOVA are nasty
Yes we are heavy into IOVA
It isn't just the biotech sector. For the past 10, almost 20 years, most corporation have trend towards downsizing or completely eliminated their R&D department in a bid to focus on the operational and business verticals. Most corporation aren't willing to underwrite R&D risk anymore. This has led to the rise and flourishing of startups that, if successful, are acquired, to be integrated into the core business of the buying company. I had a good part of my feet on the venture capital side and quant side of my professional career. **Iova is worth looking into.** They have two lines of product: Amtagvi (FDA approved for advanced melenoma with best in - class ORR, with consistency shown years after FDA approved) and Proleukin. >**52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate** >SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi^(®) (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable or metastatic) melanoma. Amtagvi is the first one-time T cell therapy for a solid tumor cancer as well as the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and targeted therapy, where applicable. >The real-world results were highlighted in an [oral presentation](https://www.iovance.com/scientific-publications-presentations/) at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT^(®)) and the Center for International Blood and Marrow Transplant Research (CIBMTR^(®)) in Salt Lake City, UT. >Forty-one evaluable patients with previously treated advanced melanoma received commercial Amtagvi according to the U.S. prescribing information at four authorized treatment centers. The physician-assessed confirmed objective response rate (ORR) was 44% (18/41) and the disease control rate was 73% (30/41). Response rates were higher with earlier Amtagvi treatment. The ORR was 52% (12/23) following two or fewer lines of therapy compared to an ORR of 33% (6/18) after three or more lines of therapy. The unprecedented real-world response rates also improved upon the 31% ORR in the C-144-01 clinical trial that supported the U.S. FDA accelerated approval of Amtagvi. >Lilit Karapetyan, MD, MS of H. Lee Moffitt Cancer Center & Research Institute stated, “The real-world response rate builds on existing clinical data and supports consideration of lifileucel as soon as possible after immune checkpoint inhibitor treatment. An overall response rate of 44% was observed in the full cohort, with a 52% response rate among patients treated in earlier lines of therapy. I am encouraged by the potential for an increasing number of patients to benefit as adoption of TIL therapy continues.” >Daniel Kirby, Chief Commercial Officer of Iovance, stated, “The real world Amtagvi data with impressive response rates, paired with unprecedented five-year durability and survival data, demonstrate a best-in-class profile and better outcomes in patients treated earlier.” >Previously treated advanced melanoma represents an unmet medical need with more than 8,000 annual U.S. deaths.^(1) More than half of patients treated with first line standard of care will progress within 12 months.^(2) The U.S. FDA granted accelerated approval for Amtagvi in February 2024 based on ORR and duration of response (DOR) from the C-144-01 clinical trial. The published [final five-year analysis](https://ascopubs.org/doi/10.1200/JCO-25-00765) demonstrated unprecedented durability and follow-up in previously treated advanced melanoma patients, with \~31% ORR, median DOR of 36+ months, and a 20% five-year overall survival.^(3) Iovance is conducting TILVANCE-301, a Phase 3 clinical trial in frontline advanced melanoma, to confirm clinical benefit. >1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2025 Estimates. [https://seer.cancer.gov](https://seer.cancer.gov/) (accessed February 2026) 2. Larkin J, et al. NEJM; Robert C, et al. Lancet; Tawbi HA, et al. NEJM 3. Medina T, et al. JCO Source: [https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment](https://ir.iovance.com/news-releases/news-release-details/best-class-real-world-data-support-early-amtagvir-treatment) **Using what made Amtagvi/ lifileucel successful, Iova has made positive in-road into cell therapy for soft tissue sarcomas with a high 50% ORR.** >Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas *50% Objective Response Rate (ORR) in Advanced Sarcomas* >*Significant Market Opportunity with More than 8,000 Patients Diagnosed* *Annually in the U.S. and Europe* >SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a [pilot clinical trial](https://clinicaltrials.gov/study/NCT05607095?cond=sarcoma&intr=TIL&rank=6) led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy. >Among the first six evaluable patients treated with lifileucel monotherapy, physician-assessed confirmed ORR by RECIST v1.1 was 50%. All evaluable patients had advanced disease, were refractory to prior therapy, and had significant disease burden, with a mean sum of diameters of 117 millimeters at baseline and a mean of more than two prior lines of therapy. Patients experienced deep responses that improved over time, consistent with lifileucel in melanoma, non-small-cell lung cancer, and other solid tumors. The safety profile was favorable and consistent with lifileucel therapy in other indications. Based on these results, Iovance plans to commence a single arm registrational trial in second-line advanced UPS and DDLPS in the second quarter of 2026 and will engage with the U.S. Food and Drug Administration (FDA) on an accelerated path to expedite approval. Iovance also plans to explore lifileucel in other high grade soft tissue sarcoma subtypes with high unmet need as part of its clinical development program. >UPS and DDLPS are high grade, aggressive soft tissue sarcomas associated with poor prognosis that impact more than 3,000 patients in the U.S. and more than 5,000 patients in Europe annually, including more than 3,500 patients with advanced disease.^(1-3) There is a high unmet medical need for new treatment options for second-line patients with recent clinical studies reporting ORRs of less than 5%, median progression-free survival (mPFS) of \~2-3 months, and median overall survival (mOS) of \~9-10 months.^(4-6) >Lauren Baker Banks, MD, PhD, Sarcoma Medical Oncologist, MSKCC, stated, “In the first clinical trial of a TIL cell therapy in UPS and DDLPS, one-time treatment with lifileucel demonstrated compelling and unprecedented response rates with the potential to address a significant unmet need in patients who are refractory to frontline standard of care. Patients with UPS and DDLPS suffer from high disease burden, poor quality of life, and a lack of effective treatments, including no approved immunotherapy options. In the second-line setting, mPFS for many patients is only a few months with mOS less than a year. We look forward to presenting these results at a medical conference in 2026.” >Dr. Brian Gastman, EVP Translational Medicine and Research at Iovance, stated, “The exciting clinical results show that lifileucel could offer a new, highly efficacious, and durable immunotherapy option in two aggressive forms of advanced sarcoma and further illustrate the promise of our TIL cell therapy platform to offer meaningful clinical benefit in multiple solid tumor cancers. Chemotherapy with extremely poor efficacy remains the second-line standard of care for these patients after progression on front-line chemotherapy. We look forward to bringing lifileucel to UPS and DDPLS patients as quickly as possible.” Source: [https://ir.iovance.com/news-releases/news-release-details/iovance-announces-positive-results-first-clinical-trial-til-cell](https://ir.iovance.com/news-releases/news-release-details/iovance-announces-positive-results-first-clinical-trial-til-cell) More: [https://ir.iovance.com/news-events/press-releases](https://ir.iovance.com/news-events/press-releases)
IOVA dipped because its main competitor got a FDA rejection. Smashed the fuck outta that buy button this week, best believe it.
They own the manufacturing and have been driving costs down. I’ve been in IOVA for nearly 3 years now. Nobody is doing what they are doing and the results for patience who are getting 0 from the transitional standard of care is amazing. This is an entire platform that could replace chemo.
IOVA acting up. Very squeezy.
long term watchlist: BUFF.V, QIMC, SLS, IOVA, NMRA, IBRX
IOVA is interesting, I looked into it after reading your comment. CTB is really low though.
Currently 90% cash waiting for ber, long commons and calls SLS IBRX CING SRPT IOVA so im cooked for 10% now. War not gonna end, figure i get biotech run or long overdue big big bear reset to the 400s and i go long.
still holding w $3.6 average. planning to buy a whole lot more biotech after selling my EONR (mainly SLS, NMRA, IOVA)
But Shkreli told me IOVA good :(
buying the dip on IOVA. They are scheduled to annouce some clinical results Q1 so kinda excited for that
IOVA clinical data releasing in q1 (11 days left)
Cry because i sold swarmer for 1.5k loss and now it's up ON, maybe shorters will destroy it tomorrow. Hope SLS IBRX IOVA SRPT and CING do better than today. Otherwise 90% cash
Yes! I'm invested in a few other cancer stocks that could go high based on current share price - MAIA, AUTL, CHRS. But IOVA is a strong contender. Outside of that I'd bet DVLT, NRXP and FEMY (heavy on this choice because they have so much going for them).
my positions: 100x LRMR, 500x IBRX + 6$ july calls, 500x IOVA + $3 june calls, 100x NMRA
LRMR IOVA IBRX SLS NMRA best biotech stocks for 2026
I'm going in with IOVA $7.5 calls in june. Their drugs and fda trials can easily push this to 10+
found IOVA on some reddit yesterday it looks like the next ibrx, but its heavily shorted so what are your thoughts
IOVA is radioactive and if you are entering now after the pump, its joever. management is terrible, financials are worse than expected, and they are going to do nothing but dilute you over time.
lemme guess. OCGN is gonna pull another IOVA just when u start cheering. been there, done that.
Lost $1k on IOVA, ofc I bought the top
IOVA had strong support at $5.10 today. Only -3.8% down. Still holding 21k shares
NMRA has a chance for a short squeeze, IOVA too
IOVA my favourite $3 dollar stock ($5 currently)
You’re never going to be rich cause even if we do give you the play you will piss it all away the next day on some other degenerate play. With that said, buy IOVA prior to their conference and likely release of 2026 guidance tomorrow. Thank me later
$IOVA I have added a couple of times. I'm genuinely curious why this one doesn't garner more attention?
IOVA at the start of its bull run, was beaten down after launch. Commercial success is happening and now indication expansion is claifying showing it as a complete platform and not just relegated for melanoma. Lots of upside ahead.
IOVA gonna squeeze deez nuts
IOVA! LFG! Up $10,000 on this stock!
IOVA short squeeze 5th day green in a row
IOVA still strong and calls always calls.
TEAM, SATL and IOVA. TEAM has been hit pretty hers and is due for a bounce back imo. SATL is a high risk high reward space play, and IOVA is a fun squeeze option (not betting much in it but still watching) I figured I’d throw some lottery tickets out there since everyone else is going boring, typical stocks. Of course buy the dip in tech and the indices, etc.
I just need IOVA to moon pls thanks
IOVA still gonna be green like it was all last week
Rotation into healthcare and other defensive sectors, IOVA strong, it’s been green every day since the start of the war.
Why did you not tell me about IOVA sooner?
At minute 8:25 from the 03/06 show Cramer says Dicks can finally blast off. Strong IOVA next week!
$IOVA Investor from Austria 7000 shares 5USD average buy in First one was at 17usd in Februar 24🤣 Never sold Dcad the way down Best buy was at 1.8USD Man what a ride Now waiting for a little drop to load more and enjoy the coming squeeze more💪
Had this on my watchlist… sorta didn’t watch close enough. I was preoccupied w/CALC, SELS, IOVA, RNXT, ONCY… & I guess RIME… had a $700 profit on that. Been Trying to enter again, too high right now imo. That $700 gets reinvested so not like I really feel that profit. Shoulda bought more SELS, IOVA. Those two may run higher. I like CALC @.60 for possible good gains. Been adding a lil. (I haven’t dabbled in Pennie’s for a few years. Ya’ll prob. know the story.). Seems the less I trade the better… have been holding a few years on APPL, V, SOFI. finally shed DraftKings. Coulda sold at $52… got out at $22, OUCH. Put the cash in more SOFI & finally got some XIACF ($4.45). Missed the RXT run… that can happen checking stocks in the afternoon. Tread carefully. GLTA!
https://www.ibtimes.com.au/iovance-biotherapeutics-iova-stock-rallies-analyst-upgrades-amtagvi-momentum-1862892 more good IOVA news 133 million shorts covering could maybe see something huge next week
IOVA on a tear, MC still undervalued.
I have over 330k shares right now. Started accumulating around the $1.60-$1.70 mark. Just became a millionaire today and this is just the beginning for IOVA. Strong close with momentum today, reaching its 52-week high. Conference next week will be huge. Imagine this could get to the point of a short squeeze if they drop some more updates or release 2026 guidance at the conference.
IMO - IOVA is a good buy under $3. Its almost doubled since start of year, is too expensive and due for a major pullback soon. They have revenues from drug sales but these are not growing and management knows it. Management declined to provide forward guidance in their last earnings call after being directly asked to by an analyst during the Q & A session. They have $300 million in cash and equivalents. Sounds like alot until you consider that they are consistently losing about $70 million a quarter. I don't know why it has had its recent price strength, but I picked up $500 worth of April $4.50 puts this morning.
Holy thank you retards for the IOVA play I've been holding for almost a year now
Let’s go IOVA! So glad I bought 3000 shares at $2
Holy shit, IOVA going absolutely parabolic. fuck the shorts.
Been saying this in here for the last week and here I am again, IOVA strong LFG!!!
IOVA get in before its too late huge short squeeze
The best performing position in my portfolio is… IOVA leaps? Really? Even success feels like failure.
IOVA telling all the shorties “get da fuck outta heah” with that opening spike. Will be on my watch list next week
From my experience with IOVA, it always drops some more before a new catalyst. But as always it could differ this time.
IOVA is my play. Lotto ticket babyyyy
I took a small position ($5k) in IOVA back in OCT 24 when it was trading at $10. I then proceeded to buy the dip. again and again and again. When it was under $2 I loaded up. Ended up with a cost average of $3.64. This was my biggest losing position for a year. Now I'm up 26%. But holy fuck now it's an unreasonable percentage of my account.
Just gonna keep sitting on these IOVA shares
been saying this yesterday IOVA short squeeze incoming
been saying this since yesterday IOVA short squeeze incoming
I mentioned IOVA here earlier, but huge short interest and up 13% today this is a short squeeze setup
IOVA up 20% short squeeze soon
IOVA turnaround story continues, LFG!
IOVA and SLS green AF!